Basic information
- CAS
63659-19-8- Standard SMILES
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl- InChIKey
CHDPSNLJFOQTRK-UHFFFAOYSA-N- Molecular formula
- C18H30ClNO3
- Average molar mass
- 343.9 g/mol
- Monoisotopic mass
- 343.1914215
Overview
Betaxolol Hydrochloride is the hydrochloride salt form of betaxolol, a beta-1-selective adrenergic receptor antagonist without intrinsic sympathomimetic activity. Betaxolol hydrochloride acts on the heart and circulatory system and decreases cardiac contractility and rate, thereby reducing cardiac output. When applied topically in the eye, it lowers intraocular pressure by reducing aqueous humor secretion.
Names & identifiers
- Preferred name
- Betaxolol Hydrochloride
- IUPAC
- 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
- English name
- Betaxolol hydrochloride
- Molecular formula
- C18H30ClNO3
- Molecular weight
- 343.89
Names & synonyms
Show more names
Database identifiers
- CAS
63659-19-8、72424-72-7- PubChem CID
- 107952
- DTXSID
DTXSID30979876- ChEMBL
CHEMBL1691- UNII
- 6X97D2XT0O
- EC Number
- 264-384-3
Properties
Computed structural properties
- Topological polar surface area
- 50.7 Ų
- Hydrogen bond donors
- 3
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 11
- Heavy atoms
- 23
- Formal charge
- 0
- Complexity
- 286
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- Melting point
- 116 ° · 116°
- storage temp.
- 2 · 2-8°C
- solubility
- 2 O: · H2O: 36 mg/mL, soluble
- form
- solid
- color
- white
- Water Solubility
- 50 mM · Soluble to 50 mM in water
- Merck
- 14 · 14,1182
- Stability
- Hygroscopic
- Major Application
- pharmaceutical (small molecule)
- InChI
- InChI=1S/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H
- InChIKey
- CHDPSNLJFOQTRK-UHFFFAOYSA-N
- SMILES
- C1(OCC(O)CNC(C)C)C=CC(CCOCC2CC2)=CC=1.Cl
- CAS DataBase Reference
- 63659 · 63659-19-8(CAS DataBase Reference)
- FDA UNII
- 6 X97D2XT0O · 6X97D2XT0O
- UNSPSC Code
- 41116107 · 41116107
- NACRES
- 24 · NA.24
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302
- Precautionary statements
- 301 · P301+P312+P330
- Hazard Codes
- Xn
- Risk Statements
- 22 · 22
- WGK Germany
- 3 · 3
- RTECS
- 9823000 · UA9823000
- HS Code
- 2922504500 · 2922504500
- Storage Class
- 11 · 11 - Combustible Solids
- Hazard Classifications
- 4 Oral · Acute Tox. 4 Oral
- Toxicity
- 50 in · LD50 in mice (mg/kg): 944 orally; 37 i.v. (Manoury)
Safety & regulation
GHS classification
GHS Classification
This chemical does not meet GHS hazard criteria for 2% (1 of 49) of reports.
Warning
H302 (98%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 49 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Betaxolol hydrochloride
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Safety data
- wgk
- 3
- rtecs
- UA9823000
- hs_code
- 2922504500
- Toxicity
- LD50 in mice (mg/kg): 944 orally; 37 i.v. (Manoury)
- risk_code
- 22
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_code
- Xn
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H302
- Hazard Classifications
- Acute Tox. 4 Oral
- Precautionary statements
- P301+P312+P330
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
BETAXOLOL HYDROCHLORIDE
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
Applications
DescriptionBetaxolol (hydrochloride) (Item No. 26285) is an analytical reference standard categorized as a β1-adrenergic receptor antagonist. Formulations containing β-adrenergic receptor antagonists have been used to enhance physical performance in athletes. This product is intended for use in analytical forensic applications. This product is also available as a general research tool .
DescriptionBetaxolol hydrochloride is a cardioselective β-adrenergic blocker, reportedly devoid of intrinsic sympathomimetic and membrane stabilizing properties. Its long duration of action permits once-daily dosing in mild to moderate hypertension. It is also being evaluated in glaucoma.
Usesantifungal
UsesBetaxolol Hydrochloride, a cardioselective β1-adrenergic blocker. An antihypertensive; antiglaucoma.
Suppliers100 total
Additional notes
DefinitionChEBI: The hydrochloride salt of betaxolol.
Related reactions
Compound notes
Loading…